Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma

Documenti analoghi

• Localized Morphea in a Pediatric Patient Successfully Treated With Topical Ruxolitinib
  di: Grace Rabinowitz, et al.
  Pubblicazione: (2025)
• Calcinosis Cutis and Delayed‐Onset Myositis in a Case of Suspected Localized Scleroderma: A Diagnostic and Therapeutic Challenge
  di: Edoardo Marrani, et al.
  Pubblicazione: (2026)
• Treatment of Epidermal Pathology in a Pediatric Patient With Keratitis–Ichthyosis–Deafness ( KID ) Syndrome With Topical Mefenamic Acid
  di: Radhika Gupta, et al.
  Pubblicazione: (2025)
• Combined Pediatric Rheumatology/Dermatology Clinics: Benefits and Challenges
  di: Jessica L. Crockett, et al.
  Pubblicazione: (2024)
• Pediatric Topical Steroid Withdrawal Syndrome: What Is Known, What Is Unknown
  di: Kripa Ahuja, et al.
  Pubblicazione: (2024)